Curcumin exerts its tumor suppressive function via inhibition of NEDD4 oncoprotein in glioma cancer cells

XUE WANG1, JIAOJIAO DENG2, JINXIA YUAN1, XIN TANG2, YUELONG WANG2, HAIFENG CHEN2, YI LIU2 and LIANGXUE ZHOU2

1School of Life Science, Shandong University, Jinan, Shandong 250100; 2Department of Neurosurgery and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan 610041, P.R. China

Received January 26, 2017; Accepted March 30, 2017

DOI: 10.3892/ijo.2017.4037

Correspondence to: Dr Yi Liu or Dr Liangxue Zhou, Department of Neurosurgery and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan 610041, P.R. China
E-mail: neurosurgeon@live.cn
E-mail: liangxuezhou@126.com

Key words: curcumin, glioma, NEDD4, invasion, apoptosis, proliferation

Abstract. Glioblastoma is the most common brain cancer in adults. It represents one of the top ten malignant tumors with an average survival time of nine months despite treatments with surgery, radiotherapy and chemotherapy. Curcumin is a phytochemical turmeric isolated from root of the Curcuma longa plant. Accumulating evidence have proved that curcumin targets numerous cancer signaling pathways. The E3 ubiquitin ligase NEDD4, neural precursor cell-expressed developmentally downregulated protein 4, is frequently overexpressed in various cancers. However, whether curcumin regulates NEDD4 expression has not been described in human cancers. Therefore, in this study, we explored the roles of NEDD4 in glioma cell proliferation, apoptosis and mobility. We further investigated whether curcumin exerts its antitumor activities via suppressing NEDD4 expression. We found that curcumin reduced the expression of NEDD4 and Notch1 and pAKT, leading to glioma cell growth inhibition, apoptosis, and suppression of migration and invasion. Moreover, deletion of NEDD4 expression enhanced the sensitivity of glioma cells to curcumin treatment. Thus, inactivation of NEDD4 by curcumin could be a promising approach for therapeutic intervention.

Introduction

Brain cancer has been proved as the leading cause of cancer death among children and adolescents (1). Cerebral glioma is the most common brain tumor in human, which represents one of the top ten malignant tumors (2). The principal features of glioma are strong angiogenesis and local invasive growth. It is often difficult to remove entire brain tumor by surgery. Glioblastoma secretes high levels of VEGF (vascular endothelial growth factor), which is responsible for the endothelial cell proliferation, blood-brain barrier permeability and angiogenesis (3,4). Many chemotherapeutic drugs cannot pass the blood-brain barrier (5). Moreover, glioblastoma is aggressive and generally resistant to therapies including surgery, radiation, and conventional chemotherapy. Although treatment options have been greatly improved for glioma during the past decades, the morbidity and mortality rates are still at a high level, and the average survival time is nine months (6). Therefore, it is critical to discover molecular targets associated with the pathogenesis of glioma and find new therapeutic agents for the treatment of glioma.

Curcumin is a yellow-gold color phytochemical turmeric isolated from root of the Curcuma longa plant (7). Multiple biological properties have been identified for this compound, including anti-inflammatory, wound healing and antineoplastic capabilities (8-10). Regarding its anticancer activity, curcumin has been described as an inducer of apoptosis and cell cycle arrest via regulating multiple cancer signaling pathways, such as NF-κB (nuclear factor-κB), Ras, AKT, Notch1, Wnt/β-catenin, FOXO1 (forkhead box protein 1), PI3K (phosphoinoside-3-kinase), and so on (11-16). It is of great interest to ascertain the molecular insight onto curcumin-mediated anticancer property.

The E3-ubiquitin ligase NEDD4, neuronal precursor cell-expressed developmentally downregulated 4-1, consists of an N-terminal C2, four WW domains and a catalytic C-terminal HECT domain. NEDD4 is responsible for substrate recognition in the poly-ubiquitination of proteins for degradation (17,18). NEDD4 regulates many physiological progresses, such as the development of neuromuscular junction (19) and neurite (20). In addition, deregulation of NEDD4 expression was observed in ischemic stroke and neurodegeneration (21,22). Notably, NEDD4-mediated protein poly-ubiquitination and degradation has been implicated in cancer development and is drawing increasing interest. It has been reported that NEDD4 is frequently overexpressed in a wide range of tumor types, such as non-small cell lung carcinomas (23), breast cancer (24), gastric carcinomas (25),...
and colorectal cancer (26). Wang et al discovered that NEDD4 promotes ubiquitin-mediated PTEN (phosphatase and tensin homologue) degradation, resulting in phosphoinositide 3-kinase (PI3K)/AKT signaling pathway activation and cell proliferation (27). They further found the reverse correlation between the expression level of PTEN and NEDD4 both in animal models and human cancer samples. NEDD4 exerts its oncogenic activities in a major type of gastric cancers and serves as an exceptional prognostic biomarker for gastric cardia adenocarcinoma and is functionally associated with metastasis (25). Studies also showed that NEDD4 is involved in FoxM1B (Forkhead box protein M1 isoform B)-induced immortalized human astrocytes transformation and GBM (glioblastoma multiforme) formation (28). Recently, NEDD4 was identified to promote migration and invasion of glioma cells through a ubiquitin-dependent proteolysis of CNrasGEFs (cyclic nucleotide-Ras guanine nucleotide exchange factors) (cyclic nucleotide-Ras guanine nucleotide exchange factors) (29). These data suggest that inactivation of NEDD4 could be an attractive approach for treatment of human cancers.

Here, we investigated the function of NEDD4 in glioma cell growth, apoptosis, migration and invasion. We further probed whether curcumin could suppress the expression of NEDD4 in glioma cells. Moreover, we aimed to determine the mechanistic role of NEDD4 in curcumin-induced glioma cell growth inhibition. Our findings could provide a therapeutic potential for treatment of patients with glioma.

Materials and methods

Cell culture and reagents. The SNB19 and A1207 human glioma cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM MGC803; Gibco), supplemented with 10% FBS and 100 U/ml penicillin/streptomycin (Hyclone) at 37°C in a humidified atmosphere (5% CO₂/95% air). Primary antibodies for NEDD4 (#2740s, 1:1,000), Notch1 (#3608s, 1:1,000), and pAkt (#13038, 1:1,000) were purchased from Cell Signaling Technology (Danvers, MA, USA). All secondary antibodies were purchased from Thermo Fisher Scientific. Monoclonal anti-tubulin (T9028, 1:5,000), curcumin (CAS no. 458-37-7, 99.5% purity), and MTI (3,4,5-dimethyl-2-thiazoyl-2, 5-diphenyl-2-H-tetrazolium bromide, CAS no. 57360-69-7) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Curcumin was dissolved in DMSO to make a 30-mM stock solution and was added directly to the medium at different concentrations. TRizol, Lipofectamine™ 2000 and plus reagents were obtained from Invitrogen (Carlsbad, CA, USA). DMEM, penicillin/streptomycin, RevertAid First Strand cDNA Synthesis kit and SYBR® Select Master mix were obtained from Invitrogen (Carlsbad, CA, USA). Monoclonal anti-tubulin (T9028, 1:5,000), curcumin (CAS no. 458-37-7, 99.5% purity), and MTI (3,4,5-dimethyl-2-thiazoyl-2, 5-diphenyl-2-H-tetrazolium bromide, CAS no. 57360-69-7) were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Cell proliferation assays. SNB19 and A1207 cells (5x10³ cells/well) were seeded in 96-well plates and cultured overnight. Then the cells were treated with different concentrations of curcumin for 48 and 72 h. The cell proliferation was measured using MTT assays according to the manufacturer's protocols. Briefly, 10 µl MTT solution (0.5 mg/ml) was added to each well, and the plates were incubated for 4 h in an incubator. The liquid supernatant was then removed and 100 µl DMSO was added to each well. The absorbance was measured at 490 nm using the Multimode Reader of SpectraMax M5 (Molecular Devices, Sunnyvale, CA, USA). Independent experiments were repeated in triplicate.

Cell apoptosis analysis. Glioma cells were seeded at a density of 2x10⁵ cells/well in 6-well plates. Various concentration of curcumin was added to each well. Cells were allowed to culture for 48 h and then harvested by centrifugation, subsequently resuspended in 500 µl of binding buffer containing 5 µl propidium iodide (PI) and 5 µl Annexin V-FITC. The stained cells were analyzed using a FACSCalibur flow cytometer (BD Biosciences, USA).

Cell cycle assays. Glioma cells were cultured in 6-well plates at a density of 2x10⁵ cells/well overnight. Curcumin was then added and allowed to incubate for another 48 h. Cells were harvested and washed with PBS, suspended with 70% ice-cold alcohol and fixed overnight. Cells were then washed and suspended with 500 µl PBS. Cells were incubated with 100 µg/ml RNase and 50 mg/ml PI (propidium iodide) at 37°C for 30 min. Cell cycle was determined with a FACSCalibur flow cytometer (BD Biosciences).

Wound healing assay. After 72-h incubation, glioma cells grew to 90% confluence. A lesion on monolayers was created with a sterile 100-µl pipette tip. Debris was removed by carefully washing with PBS. Cells were cultured for the designated time course. Images were captured at the lesion border using an inverted microscope (Olympus, IX71).

Cell invasion assay. Cell invasive capacity was performed using Transwell chamber (8-µm pore size, Corning), according to the manufacturer's instructions. Briefly, filters were precoated with 100 µl of Matrigel (BD Biosciences) diluted with serum-free medium to the final concentration of 1 mg/ml. Suitable amount of pretreated cell suspension in serum-free DMEM was added into the upper chamber. Medium (600 µl) containing 10% FBS was then added into the bottom chamber. After 20-h incubation at 37°C, the non-invasive cells in the upper chamber were removed. The invaded cells on filters were stained with Giemsa. The stained cells in each filter were captured and counted in at least six randomly-selected images.

Quantitative real-time reverse transcription-PCR (Q-PCR) analysis. The total RNA was extracted with TRizol (Invitrogen) and reverse-transcribed into cDNA by RevertAid First Strand cDNA Synthesis kit. Real-time Q-PCR was performed using Power SYBR Green PCR Master Mix and the results were calculated by 2−∆∆Ct method. The primers for NEDD4 were as follows: sense, 5'-GCT GCT AAA GGT CTC TGG TGT-3'; antisense, 5'-AGG CTT AGA TTC TGC AAC TTG-3'; Primers for GAPDH: sense, 5'-ACC CAG AAC ACT GTG GAT GG-3'; antisense, 5'-CAG TGA GCC CTG CGT TCA G-3'.

Transient transfection of plasmids and small interfering RNAs (siRNAs). Transfection of glioma cells with pcDNA3.1-NEDD4 and NEDD4 siRNAs was performed by using Lipofectamine 2000 transfection reagent, according to the manufacturer's instructions. All the transfections were performed three times independently. The siRNA sequences that targeting human NEDD4 are: Sense, 5'-GGA GAA UUA...
UGG GUG UCA ATT-3'; antisense, 5'-UUG ACA CCC AUA AUU CUC CTT-3'.

Western blot analysis. Pretreated glioma cells were harvested and lysed in cell lysis buffer supplemented with protease inhibitors. Protein concentrations were quantified using a BCA protein assay kit. Equal amount of denatured protein samples were separated by SDS-PAGE electrophoresis and then transferred onto a PVDF membrane. PVDF membranes were blocked with 5% non-fat milk and then incubated with primary antibody at 4°C overnight. After washing with TBST three times, the membranes were incubated with secondary antibody at room temperature for ~1 h. The expression of target proteins was detected by electrochemiluminescence (ECL).

Statistical analysis. All data were conducted using GraphPad Prism 4.0 (GraphPad Software, La Jolla, CA, USA) and were expressed as mean ± SD of triplicate determinants. Statistical significance was evaluated using ANOVA and differences with a P<0.05 were considered statistically significant.

Figure 1. Curcumin inhibits glioma cell proliferation, induces apoptosis and cell cycle arrest. (A) Glioma cells viability was detected after treatment with curcumin for 48 and 72 h, respectively, using MTT assay. *P<0.05, compared to the control groups treated with DMSO. (B) Left panel, curcumin-induced glioma cell apoptosis was accessed by flow cytometry. Right panel, quantitative results are illustrated for apoptosis. **P<0.01 vs control. (C) Left panel, curcumin-triggered glioma cell cycle arrest was measured by flow cytometry. Right panel, quantitative results are illustrated for G2/M phase. *P<0.05, **P<0.01 vs control.
Results

Curcumin inhibits glioma cell proliferation. Curcumin has been reported to inhibit cell growth in numerous human cancers. In this study, glioma cells were treated with different concentrations of curcumin for 48 and 72 h, respectively. MTT assays were performed to detect whether curcumin exerts anti-proliferation in SNB19 and A1207 glioma cells. The MTT results showed that curcumin inhibited glioma cell growth in a time- and dose-dependent manner (Fig. 1A). Our results clearly proved that curcumin exhibited its anti-proliferation activity in glioma cells.

Curcumin promotes apoptosis of glioma cells. It has been reported that curcumin caused cell proliferation inhibition partly due to increased apoptosis. Then we determined whether curcumin could promote cell apoptosis in glioma cells. Annexin V-FITC/PI apoptosis assay was conducted in SNB19 and A1207 glioma cells treated with curcumin for 48 h. Flow cytometer results showed that curcumin triggered glioma cell apoptosis in a dose-dependent manner (Fig. 1B). For instance, 15 and 20 µM curcumin treatments led to apoptosis from 6.9% of control group to 15.75 and 28.85% in A1207 cells (Fig. 1B). Similar increased apoptosis by curcumin treatment was observed in SNB19 cells. Our results indicated that curcumin triggered glioma cell apoptosis.

Curcumin induced cell cycle arrest. To further determine the mechanism of curcumin-induced anti-proliferation in glioma cells, cell cycle analysis was conducted by PI staining and flow cytometry in both glioma cells after curcumin treatment. We observed that curcumin arrested cell cycle at G2/M phase in
both glioma cell lines (Fig. 1C). For instance, 20 µM curcumin treatment caused G2/M phase from 6.16% in control group to 50.76% in A1207 cells (Fig. 1C). In line with this, 15 µM curcumin led to increased G2/M phase from 19.87 to 64.03% in SNB19 cells (Fig. 1C). These results suggest that curcumin arrested cell cycle at G2/M phase in glioma cells.

Curcumin inhibits cell migration and invasion in glioma cells. To examine the effect of curcumin on glioma cell motility, wound healing and Transwell assays were performed in both A1207 and SNB16 cells, respectively. Cell migration was significantly inhibited by curcumin treatment in both glioma cells (Fig. 2A). Moreover, invasion ability of glioma cells was also suppressed by curcumin (Fig. 2B). Our results demonstrated that curcumin could inhibit cell glioma cell motility abilities.

Curcumin suppressed NEDD4 expression in glioma cells. Since NEDD4 has been demonstrated to be a key oncoprotein in tumorigenesis, we hypothesized that NEDD4 may also be involved in the curcumin-mediated inhibition of cell growth and invasion in glioma cells. Q-PCR and western blot analysis were performed to measure the expression levels of NEDD4 after 48-h treatment of curcumin in both A1207 and SNB16 cell lines. As shown in Fig. 3A, NEDD4 mRNA levels were downregulated in A1207 and SNB19 cells in the presence of
curcumin. Subsequently, western blot analysis revealed that NEDD4 protein levels were significantly suppressed after a diluted concentration of curcumin treatment (Fig. 3B and C). In agreement with our hypothesis, NEDD4 was involved in the cytotoxic effect of curcumin on glioma cells. We further validated whether the suppression of NEDD4 by curcumin could affect the downstream targets of NEDD4. We examined the alterations of Notch1 and pAKT proteins in the presence of curcumin in glioma cells. The results showed that curcumin markedly downregulated the expression of Notch1 and pAKT.

Figure 4. Overexpression of NEDD4 enhances glioma cell proliferation, suppresses cell apoptosis and increases cell invasion. (A) Glioma cell growth was measured by MTT assay after NEDD4 overexpression in combination with 15 µM curcumin treatment for 72 h. \( P<0.05 \), vs control; \( P<0.05 \) vs curcumin treatment or NEDD4 cDNA transfection. (B and C) Apoptotic cells were accessed by flow cytometry after NEDD4 overexpression in combination with 15 µM curcumin treatment for 48 h. \( P<0.05 \), vs control; \( P<0.05 \) vs curcumin treatment or NEDD4 cDNA transfection. (D) Cell invasion were detected by Transwell chamber assay after NEDD4 overexpression in combination with 15 µM curcumin treatment for 20 h. \( P<0.05 \), vs control; \( P<0.05 \) vs curcumin treatment or NEDD4 cDNA transfection.
in both glioma cell lines (Fig. 3B and C). Taken together, our findings supported that curcumin reduced the expression of NEDD4 in glioma cells.

**Overexpression of NEDD4 promotes cell proliferation.** To further determine whether the expression of NEDD4 was associated with the curcumin-induced cytotoxic effect on glioma cells, the overexpression of NEDD4 by its plasmid was performed. Glioma cells were transfected with NEDD4 cDNA or empty vector as control in the presence of curcumin. MTT assay showed that NEDD4 overexpression significantly promoted glioma cell proliferation, and curcumin-induced cell growth inhibition was partly blocked (Fig. 4A). The results from Annexin V-FITC/PI apoptosis assay showed that NEDD4 overexpression significantly decreased apoptosis in both glioma cell lines and annulled curcumin-induced apoptosis (Fig. 4B and C). We also investigated the effect of NEDD4 overexpression on cellular invasive and migratory properties of glioma cells. Transwell assay showed that overexpression of NEDD4 enhanced the invasion abilities of glioma cells (Fig. 4D). Notably, NEDD4 overexpression rescued curcumin-induced cell invasion suppression to a certain degree (Fig. 4D). Moreover, we observed an increased migration of glioma cells after NEDD4 cDNA transfection, using wound healing assay (Fig. 5A). Consistently, NEDD4 overexpression abolished curcumin-caused cell mobility inhibition. We then detected the protein levels of Notch1 and pAKT. We found that transfection of NEDD4 cDNA significantly induced Notch1 and pAKT level in both glioma cell lines (Fig. 5B). Strikingly, curcumin-induced Notch1 and pAKT level suppression was partially ablished by NEDD4 cDNA transfection (Fig. 5B). These results provide evidence that curcumin exhibits anti-tumor activity in glioma cells through regulation of NEDD4 and Notch1 and pAKT.

**Silence of NEDD4 by siRNA transfection sensitizes glioma cells to curcumin treatment.** Furthermore, we examined whether co-transfection of NEDD4 siRNA enhanced curcumin-
mediated tumor suppressive function. We found that glioma cells proliferation was markedly suppressed after NEDD4 siRNA silencing (Fig. 6A). The combination of curcumin with NEDD4 depletion strengthened cell viability inhibition to a greater degree than curcumin alone or siRNA transfection alone. Next, we found that NEDD4-silenced glioma cells proliferation, increased cell apoptosis and represses cell invasion. (A) MTT assay was performed to detect the effect of NEDD4 downregulation in combination with 15 µM curcumin treatment on glioma cell growth for 72 h. *P<0.05, vs control; #P<0.05 vs curcumin treatment or NEDD4 siRNA transfection. (B and C) Apoptotic cells were detected by flow cytometry in glioma cells after NEDD4 siRNA transfection and 15 µM curcumin treatments for 48 h. *P<0.05, vs control; #P<0.05 vs curcumin treatment or NEDD4 siRNA transfection. (D) Invasive cells were counted by Transwell chamber assay after NEDD4 siRNA transfection and 15 µM curcumin treatment for 20 h. *P<0.05, vs control; #P<0.05 vs curcumin treatment or NEDD4 siRNA transfection.
were markedly sensitive to spontaneous and curcumin-induced apoptosis (Fig. 6B and C). Thereafter, we also observed that downregulation of NEDD4 significantly suppressed cellular invasive and migratory abilities of glioma cells (Figs. 6D and 7A). More importantly, NEDD4 silence together with curcumin treatment disturbed cell invasion and migration rate to a higher degree. Subsequently, we found that downregulation of NEDD4 decreased the expression of Notch1 and pAKT after siRNA silencing of NEDD4 in both glioma cell lines (Fig. 7B and C). These results indicated that NEDD4 is involved in...
curcumin-mediated cell growth inhibition, apoptosis, invasion and mobility suppression in glioma cells.

Discussion

Curcumin is used in complementary oncology as it influences cell cycle arrest, proliferation, and apoptosis in a variety of cancers (30). It has been reported for its pleiotropic effects on cellular signaling pathways (10). Recently, curcumin was determined to sensitize human gastric cancer cells to 5-fluorouracil through inhibition of the NF-κB survival signaling pathway (31). In pancreatic cancer cells, curcumin suppressed cell growth, inhibited mobility, and induced apoptosis via downregulating YAP and TAZ expression and subsequently suppressed Notch-1 expression (32). Curcumin inactivated FoxM1 and induced human acute myeloid leukemia (AML) growth inhibition, enhanced angiogenesis and chemosensitivity (33). Interestingly, Lim and colleagues recently demonstrated that curcumin is conductive to the COP9 signalosome 5-mediated ubiquitination and degradation of PD-L1 (programmed cell death-ligand 1) and as a result sensitized cancer cells to anti-CTLA4 therapy (34). The potential application value of curcumin in neural tumors was supported by previous studies, which showed the antitumor activity of this natural compound in vitro and in vivo (35-39). It was reported that transcription of the p21 (Waf1/Cip1) gene is activated by Egr-1 (early growth response-1) in response to curcumin treatment (39). Curcumin exerts anti-proliferative, anti-migratory, and anti-invasive properties against malignant gliomas via decreasing p-STAT3, c-Myc and proliferation marker Ki-67 (40). Wang et al found that curcumin suppresses glioma cell growth and invasion and induces apoptosis by downregulation of Skp2 (S-phase kinase associated protein 2) pathway (41). It was also reported that curcumin suppresses the SHH (Sonic Hedgehog)/GLI1 signaling pathway, and microRNA-326 enhances the chemo-sensitivity of glioma cells to curcumin in vitro and in vivo (42,43). In this study, we found that curcumin exerts its antitumor activities via downregulation of NEDD4/Notch1 signaling.

NEDD4 has been reported to play an oncogenic role in tumor cell growth. NEDD4 is frequently overexpressed in a wide variety of tumors. Early studies revealed that, as an E3-ubiquitin ligase, NEDD4 promotes ubiquitination and subsequent degradation of PTEN, enhances cell proliferation by activating PI3K/AKT signaling pathway (27). In gastric cardia adenocarcinoma (GCA), NEDD4 is overexpressed in major GCA tumors, while knockdown of NEDD4 in gastric cancer cell lines markedly inhibited the gastric cancer cell migration and invasion (25). On account of its oncogenic role in GCA, NEDD4 could serve as an exceptional prognostic biomarker for GCA. Recently, NEDD4 was reported to target CINrasGEF-mediated decitabine invasion-promoting activity in MGC803 gastric cancer cells (44). In glioma cells, NEDD4 facilitates migration and invasion of U251 and U87 cells through triggering CINrasGEF, but has no effects on glioma cell proliferation and apoptosis (29). Studies also showed that overexpression of FoxM1B upregulates NEDD4 in immortalized human astrocytes, leading to cellular transformation and full malignant phenotype formation (28). Increased expression of important molecules for tumor growth, such as survivin, cyclin D1, and cyclin E, were also observed in immortalized human astrocytes. In the present study, we found that overexpression of NEDD4 in A1207 and SNB19 glioma cell lines enhanced cell growth, whereas the elimination of NEDD4 expression by curcumin treatment or siRNA silencing inhibited glioma cell proliferation. Deletion of NEDD4 expression enhanced the sensitivity of glioma cells to curcumin treatment. Moreover, we observed that overexpressed NEDD4 enhanced cell migration and invasion in both glioma cells. On the contrary, deletion of NEDD4 retarded glioma cell motility. Taken together, our data showed that NEDD4 is involved in regulation of cell proliferation, migration and invasion in A1207 and SNB19 glioma cells.

In conclusion, due to the oncogenic property of NEDD4 in glioma, inactivation of NEDD-1 by natural compounds or other small molecule inhibitors could be a promising approach for therapeutic intervention. Although curcumin exerts its antitumor activities in a variety of human cancers, it is worth noting that the therapeutic application of curcumin is restricted due to its poor absorption and unsatisfactory pharmacokinetics (45). Hence, it is necessary to search for new formulation solutions and synthesize novel curcumin analogues to improve the biopotency and to overcome the blood-brain barrier. Importantly, glioma mouse models are required to determine whether curcumin exhibits its antitumor activities via suppressing the NEDD4 signaling. Ubiquitin ligases have attracted great attention as potential therapeutic targets (46,47). One compound, heclin (HECT ligase inhibitor) was recently described to inhibit a range of HECT ligases in vitro and kill growing cells by prolonged exposure (48). However, to obtain successful small molecule inhibitors of NEDD4, the complexity of the ubiquitin system and target specificity should be considered.

Acknowledgements

This study was supported by National Natural Sciences Foundation of China (81372446) and National S&T Major Project (2013ZX09301304-007).

References


